Designation of Chlormethine Valchlor as an orphan drug - Actelion Pharmaceuticals Australia Pty Ltd

Overview

The Therapeutic Goods Act 1989, enacted by the Commonwealth of Australia Parliament, addresses the regulation of therapeutic goods, including medicines, medical devices, and blood. This legislation was introduced to ensure that therapeutic goods available in Australia are safe, of high quality, and that the benefits outweigh the risks for their intended use. In particular, the Act provides a framework for the assessment, approval, and monitoring of therapeutic goods to protect public health. The Therapeutic Goods Administration, operating under the auspices of the Department of Health, is responsible for administering the Act and ensuring compliance with its provisions. In 2015, the Therapeutic Goods Administration designated Chlormethine VALCHLOR as an orphan drug for the treatment of cutaneous T cell lymphoma, under the authority conferred by the Therapeutic Goods Regulations 1990. This designation recognises the need for specialised therapeutic products for rare diseases and conditions that affect a small number of people, facilitating their development and availability. The policy objective of this designation is to encourage research, development, and availability of treatments for conditions that might otherwise be neglected due to their low prevalence.

Scope and Application

The Therapeutic Goods Act 1989, as referenced in the designation of Chlormethine VALCHLOR as an orphan drug, applies to the regulation of therapeutic goods within the Commonwealth of Australia. This legislation is administered by the Therapeutic Goods Administration, which is a part of the Department of Health. The Act applies to a broad range of entities including pharmaceutical companies, medical device manufacturers, and health practitioners who are involved in the research, development, manufacture, importation, supply, or advertising of therapeutic goods. The scope of this particular designation extends specifically to the treatment of cutaneous T cell lymphoma using Chlormethine VALCHLOR, a topical gel form, by identifying it as an orphan drug. This special designation is intended to encourage the development of treatments for rare diseases by providing certain incentives and expedited regulatory processes. The geographic and jurisdictional reach of this Act is national, applying uniformly across all states and territories of Australia. There are no exclusions, exemptions, or thresholds explicitly stated in this designation, but the broader Act does provide for various exclusions and exemptions depending on the nature of the therapeutic goods in question. The application and enforcement of this Act may be further detailed and extended through subordinate instruments such as regulations and guidelines issued by the Therapeutic Goods Administration.

Key Provisions

The Therapeutic Goods Act 1989, through its regulations, facilitates the designation of certain therapeutic goods as orphan drugs, which is particularly significant for rare diseases. In this instance, section 16J of the Therapeutic Goods Regulations 1990 empowers the Delegate of the Secretary to designate a medicine as an orphan drug if it meets specific criteria, such as treating a rare disease or condition. Here, Chlormethine VALCHLOR has been designated as an orphan drug (subregulation 16J(2)) for the treatment of cutaneous T cell lymphoma, a rare form of skin cancer. This designation acknowledges the importance of developing treatments for rare diseases and can provide certain incentives to the sponsor, Actelion Pharmaceuticals Australia Pty Ltd. The obligations imposed by the designation of Chlormethine VALCHLOR as an orphan drug include ensuring that the therapeutic good meets all safety, quality, and efficacy standards as outlined in the Therapeutic Goods Act 1989 and the Therapeutic Goods Regulations 1990. The sponsor, Actelion Pharmaceuticals Australia Pty Ltd, must submit necessary documentation and data to support the orphan drug designation, including evidence that the drug is intended for a rare disease and that there are no satisfactory alternative treatments available. Additionally, the sponsor must comply with any additional requirements that may be stipulated by the Therapeutic Goods Administration (TGA) to maintain the orphan drug status. Failure to comply with the provisions of the Therapeutic Goods Act 1989 or the Therapeutic Goods Regulations 1990 can result in significant consequences. Under the Act, breaches may lead to civil or criminal penalties. For example, section 27 of the Act provides for civil penalty provisions where a person is found to have contravened certain provisions, which can include substantial fines. Furthermore, section 32 imposes criminal penalties for serious offences, such as manufacturing or supplying therapeutic goods that do not comply with the Act, which can result in imprisonment. The specific penalties for breaches depend on the nature and severity of the offence, with maximum penalties outlined in the relevant sections of the Act and Regulations.